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ABSTRACT 
 
Treatment for multiple myeloma (MM) has changed beyond recognition over the past two decades. 
During the early 1980s, MM inevitably resulted in a slow progressive decline in quality of life until 
death after about 2 years, while today patients can expect a 50% chance of achieving a complete 
remission, median survival of 5 years, and a 20% chance of surviving longer than 10 years. An 
international expert opinion meeting (including members of the GIMEMA and DSMM study 
groups) was held in 2009. One of the outcomes of the meeting was the development of a consensus 
statement outlining contemporary optimal clinical practice for the treatment of MM. The 
international panel recommended that the state of the art therapy for MM should comprise: (a) 
evidence-based supportive care, (b) effective and well-tolerated chemotherapeutic regimens, (c) 
autologous hematopoietic stem cell transplant (ASCT) for patients suitable for intensive 
conditioning therapy, and (d) evidence-based incorporation of novel anti-MM agents. Maintenance 
strategies have also become increasingly important for the prolongation of remission after front-line 
therapies. In addition, improved understanding of the biology of MM has led to the development of 
novel biological therapeutic agents such as thalidomide, lenalidomide, bortezomib, and others. 
These agents specifically target intracellular mechanisms and interactions, such as those within the 
bone marrow microenvironment, and have been integrated into MM treatment. This report reviews 
recent clinical advances in the treatment strategies available for MM and provides an overview of 
the state of the art management of patients with MM. 
 
 
Introduction 
 
Multiple myeloma (MM) is a mature B-cell-lymphoid neoplasm and accounts for approximately 
10% of all hematologic neoplasias [1,2]. It is characterized by the monoclonal proliferation and 
accumulation of plasma cells (PCs) in the bone marrow (BM) and an excess of secreted monoclonal 
immunoglobulins (paraprotein or M-band) [1–3 ]. MM is thought to be invariably preceded by a 
premalignant phase, monoclonal gammopathy of undetermined significance (MGUS) [4], which is 
present in more than 3% of the general population above the age of 50 years and progresses to MM 
at a rate of 1% per year (Figure 1). The annual incidence of MM is 4.3 per 100 000, with a higher 
prevalence of both MM and MGUS in Western countries. In general, these plasma cell dyscrasias 
affect males slightly more frequently than females, and are twice as common in blacks than in 
whites. The median age of patients with MM at diagnosis is 69 years for men and 72 years for 
women. The etiology of MM is largely unknown; however, familial/genetic predisposition, 
radiation, benzene, other organic solvents, herbicides, and insecticides are considered by some to 
play a role [1–3 ,5–7 ]. 
 
 
Figure 1. Clinical evolution and molecular pathogenesis of MM (figure modified according to 
illustrations of Sirohi et al., 2004 [184] and Harousseau et al., 2009 [185]), illustrating the 
disease evolution from MGUS to smoldering-, intramedullary-, and extramedullary myeloma 
and eventually plasma cell leukemia, correlating with defined molecular events as depicted. 
MGUS, monoclonal gammopathy of undetermined significance; NFκB, nuclear factor κB; Ig, 
immunoglobulin. 
 
 
 
In the majority of patients a paraprotein is detectable in the blood serum and/or urine. More 
advanced stages of MM typically present with skeletal destruction manifesting as osteolytic lesions, 
osteopenia, and/or pathologic fractures. Other common clinical features include renal insufficiency, 
hypercalcemia, myelosuppression with anemia, bleeding, immunodeficiency, and hyperviscosity. 
The Mayo Clinic and International Myeloma Working Group (IMWG) have developed simplified 
criteria for the diagnosis of symptomatic MM, whereby the following three criteria must be met: (1) 
the presence of a paraprotein in the serum and/or urine, (2) the presence of at least 10% clonal bone 
marrow plasma cells, and (3) the presence of related organ or tissue impairment (ROTI), for 
example hypercalcemia, renal impairment, anemia, and/or bone disease (CRAB). 
The clinical staging system previously proposed by Durie and Salmon is based on factors 
correlating with tumor mass [1–3 ,8], and has largely been replaced by the International Staging 
System (ISS) [9]. Besides disease stage, other important prognostic factors that define patients as 
high-risk or standard-risk include: deletion of chromosome 13 or hypodiploidy on conventional 
karyotyping; deletion of chromosome 17p−, t(4;14), or t(14;16) on interphase karyotypic analysis 
(fluorescence in situ hybridization, FISH); and a plasma labeling index of ≥3% [10]. The presence 
of any one of these risk factors identifies an individual patient as having high-risk MM, where the 
median overall survival (OS), even with tandem stem cell transplant (SCT), is only 2–3 years, as 
opposed to 5 or more years for those patients with MM with standard-risk disease [10]. Overall the 
median OS is 3–5 years, and the main goals of treatment are the achievement of higher and more 
prolonged complete remission (CR) rates that translate into better long-term OS and improved 
quality of life with fewer MM-associated symptoms [1,11]. 
In randomized trials, high-dose chemotherapy and autologous hematopoietic stem cell transplant 
(ASCT) produces an OS advantage compared to conventional chemotherapy [12–15 ], and patients 
with high-risk MM, when eligible, are now routinely offered combination induction therapies 
incorporating new agents followed by ASCT. Subsequent strategies including reduced intensity 
conditioning (RIC)-allogeneic (allo)-SCT in selected patients [10,16,17] and/or the use of 
maintenance therapy after ASCT are now being increasingly incorporated into the treatment 
paradigm. Allo-SCT is thought to be potentially curative; however, while long-term results are still 
awaited it is clearly evident that the introduction of RIC-regimens has decreased treatment related 
morbidity and mortality (TRM) considerably when compared to previously utilized myeloablative 
conditioning approaches [16,17]. The introduction of (a) earlier ASCTs; (b) tandem transplants 
within clinical trials; and (c) novel anti-MM drugs as part of primary upfront therapy and/or 
maintenance therapy is hoped to further improve the outcome of MM in the near future. These more 
intensive treatment strategies can also be contemplated in selected older patients with increasing 
success. This can be attributed to advances in reduced intensity induction regimens and, in 
particular, improved supportive care and more informative comorbidity assessment strategies 
[1,11,18,19]. 
Novel anti-MM drugs have also expanded therapeutic prospects, and current trials are evaluating a 
range of innovative agents including immunomodulatory drugs (IMiDs, e.g. pomalidomide), 
proteasome inhibitors (S-2209, NPI-0052), multikinase inhibitors, farnesyl transferase inhibitors, 
histone deacetylase (HDAC) inhibitors (Vorinostat, KD7150, MS-275, Tubacin, LBH589 
[Panobinostat®]), heat shock protein-90 (HSP-90) inhibitors (NVP-AUY922), various monoclonal 
antibodies, and PI-3K/PKD/mTOR (phosphatidylinositol 3-kinase/protein kinase D/mammalian 
target of rapamycin) inhibitors (NVP-BEZ235) that aim to further improve the outcome for patients 
with MM. 
 
 
Design and methods 
 
One of the principal challenges faced today in the management of MM is how to best exploit 
diagnostic information so as to best inform prognosis and the selection of therapies, thus better 
defining the optimal use of new anti-MM agents and their various combinations in the different 
stages of the disease. Furthermore, as the management of MM is rapidly changing, guidelines that 
incorporate strategies for the optimal management of the disease are becoming increasingly 
important and help us to employ the best available treatments for patients with MM. Guidelines 
currently available include those from the National Comprehensive Cancer Network [20], UK 
Myeloma Forum, Nordic Myeloma Study Group, and the International Myeloma Foundation, 
recommendations based on expert opinion meetings [21], and various hematology groups (e.g. 
Deutsche Gesellschaft für Hämatologie und Onkologie [DHGO]; www.dgho.de/cms.php?id=705 ) 
[22–25 ]. 
An international expert opinion meeting was held in Stresa, Italy, from 17 to 19 May 2009, which 
brought together members of the German (Deutsche Studiengruppe Multiples Myelom, DSMM) 
and Italian (Gruppo Italiano Malattie Ematologiche dell'Adulto, GIMEMA) MM study groups and 
an international faculty with extensive clinical and scientific experience in MM. Different 
consensus panels coordinated by two chairmen defined several areas for MM-specific 
recommendations: (1) front-line therapy for young patients (Einsele, Cavo); (2) front-line therapy 
for elderly patients (Palumbo, Straka, Knop); (3) treatment of relapsed and refractory patients 
(Boccadoro, Kropff); (4) the use of novel agents (Morabito, Gramatzki, Spencer); (5) the role of 
allogeneic stem cell transplant (Bruno, Bunjes); (6) guidelines and management of side effects 
(Engelhardt, Patriarca, Polliack); and (7) bone disease, biobanking, cytogenetics, and molecular 
studies (Sezer, Hajek, Omede, Neri). These experts reviewed published literature and then 
expressed their recommendations based on scientific evidence and clinical practice experience. The 
expert panels, where applicable, based recommendations on the results of at least one large 
prospective randomized trial. If evidence from phase 3 studies was unavailable in a specific area, 
the expert panel expressed suggestions based on the results of prospective non-randomized studies, 
clearly indicating the need for further data. Thus, these recommendations reflect expert opinion, 
with the summaries provided here illustrating how scientific results are perceived by medical 
practitioners and how they are subsequently applied in daily clinical practice. 
 
 
To treat or not to treat: clinical considerations for initiation of 
therapy including diagnostics 
 
 
 
 
 
Criteria that differentiate MGUS, asymptomatic (smoldering) MM, symptomatic (including non-
secretory) MM, solitary plasmacytoma, and extramedullary (EM) MM have been defined by the 
IMWG [8]. MGUS is defined by the presence of a paraprotein <30 g/L, BM clonal plasma 
cells <10%, but no evidence of MM, other B-cell proliferative disorders, or light-chain (AL) 
amyloidosis. In smoldering MM the paraprotein is ≥30 g/L and/or clonal BM plasma cells are ≥10%, 
without related organ or tissue impairment (ROTI). MM exhibits some or all of the pathologic 
findings as described above, as well as ROTI. Non-secretory MM is characterized by the absence of 
a paraprotein in the serum and urine, but displays BM plasmacytosis and ROTI. To precisely 
differentiate these distinct entities, the investigations outlined in Table I are required, and thereby 
facilitate appropriately timed therapeutic intervention. 
 
Table I. Diagnostic criteria for MGUS, smoldering or indolent multiple myeloma (MM), and 
symptomatic MM. 
 
The requirement for a simplified prognostic scoring system has been met by the introduction of the 
International Staging System (ISS) as devised by Greipp et al. [9] that incorporates serum albumin 
and β2-microglobulin at the time of diagnosis. Furthermore, advances in both metaphase 
cytogenetics and FISH on interphase cells have improved the ability to detect prognostically 
relevant chromosomal abnormalities. FISH-based abnormalities including 17p deletion, t(4;14), and 
t(14;16) and the detection with metaphase cytogenetics of del13 or hypoploidy all confer a worse 
prognosis, and, although less readily available, a plasma cell labeling index (PCLI) >3% similarly 
correlates with a poor outcome. These prognostic factors, and potentially other novel predictive 
markers currently being assessed, help to define different prognostic groups of MM patients, may 
identify novel targets for specific anti-MM treatment strategies, and also facilitate the stratification 
of patients for innovative treatment strategies and clinical trials [18,19,26,27]. 
Optimizing response via the attainment of a CR (complete response) and its valid recognition are 
important goals of contemporary MM therapy. CR is currently defined according to European 
Group for Blood and Marrow Transplantation (EBMT) or IMWG criteria, but can be more 
stringently defined by the incorporation of multiparameter flow cytometry (MFC), thus allowing for 
the more accurate assessment of ‘minimal residual disease’ (MRD). MRD assessment is standard in 
many hematologic malignancies, but is still considered investigational in MM. Prospective analyses 
of the prognostic importance of MRD detection by MFC in patients with newly diagnosed MM 
uniformly treated with ASCT have been shown to be of importance, since progression-free survival 
(PFS) and OS were longer in patients who were MRD-negative versus MRD-positive at day 100 
after ASCT. Furthermore, multivariate analysis identified MRD status by MFC at day 100 after 
ASCT as the most important independent prognostic factor for PFS and OS, illustrating the clinical 
impact of MRD detection and therefore the need for further refinement of MM response criteria 
incorporating MRD analyses [28]. 
A report from the European Myeloma Network (EMN) outlined technical MFC recommendations, 
including: (1) CD38, CD138, and CD45 should all be included in at least one tube for PC 
identification and enumeration; the primary gate should be based on CD38 vs. CD138 expression; 
(2) after treatment, clonality assessment is only likely to be informative when combined with 
immunophenotypic findings to detect abnormal cells, and MFC should be used for demonstrating a 
stringent CR; (3) for detection of abnormal PCs a minimal panel should also include CD19 and 
CD56, but a preferred panel would also include CD20, CD117, CD28, and CD27; (4) discrepancies 
between the percentage of PCs detected by MFC and light microscopy and cytology are primarily 
related to sample quality; therefore, it is important to determine that marrow elements are present in 
follow-up samples, particularly normal PCs in the MRD-negative cases [29]. 
 
 
Induction therapy for young patients 
 
Induction therapy prior to ASCT is aimed at achieving de-bulking of disease and symptom control, 
and facilitates the collection of peripheral blood stem cells (PBSCs). However, the prolonged use of 
alkylating agents, dense BM infiltration, prior irradiation, advanced age, and elevated plasma 
viscosity are all factors which may impair stem cell procurement and subsequent engraftment [30–
32 ]. Therefore, if ASCT is contemplated, prolonged alkylating agent exposure should be avoided 
[30]. Furthermore, the prolonged use of alkylating agents prior to PBSC collection also increases 
the risk of myelodysplasia (MDS) post-transplant. 
VAD (vincristine, doxorubicin, dexamethasone) chemotherapy has been used as an induction 
regimen for many years; however, PBSC mobilization may be better facilitated by alternative 
regimens, such as IEV (ifosfamide, etoposide, epirubicin), CEV (cyclophosphamide, etoposide, 
epirubicin), or cyclophosphamide alone [30,33]. Furthermore, while objective response rates 
achieved with VAD are in the range of 40–70%, its administration is demanding, principally 
because infusional adriamycin and vincristine require a central line, with the associated risk of 
infective and thrombotic complications. Response rates with dexamethasone alone [34] are in the 
order of 40–50%, and associated with less treatment-related toxicity. These factors and the 
introduction of several newer induction regimens mean that VAD is no longer recommended as 
induction therapy. 
Several newer induction regimens currently that are suitable prior to ASCT include bortezomib-
based regimens (e.g. VCD [bortezomib, cyclophosphamide, dexamethasone] [35], VTD 
[bortezomib, thalidomide, dexamethasone], or PAD [bortezomib, adriamycin, dexamethasone]) 
[21,24,36], thalidomide/dexamethasone (Thal/Dex) [36,37], or lenalidomide/dexamethasone 
(Rev/Dex [given as RD or Rd]; e.g. four cycles of Rd before cyclophosphamide mobilization and 
melphalan 200 (MEL200) [38]); (Table II) the latter eventually may be combined with 
cyclophosphamide. However, the potential detrimental impact of lenalidomide on subsequent PBSC 
collection requires clarification in appropriately designed clinical trials. 
 
 Table II. First-line treatment in newly diagnosed multiple myeloma (phase III studies). 
 
 
Thalidomide and thalidomide analogs 
 
 
 
 
 
Initially given in relapsed MM as a single agent, thalidomide has been shown to induce overall 
response rates (ORRs) of approximately 30% [39]; however, when combined with dexamethasone 
and/or alkylators, increased response rates are seen [40]. As thalidomide and its analogs are more 
effective with earlier treatment initiation, they have been included in a variety of induction 
schedules with substantially lower thalidomide doses (100–200 mg/day), thereby minimizing 
toxicity [40–42 ]. It is possible that this dose may be able to be lowered even further in newer 
combination strategies [40–44 ]. The OPTIMUM study compared the tolerability and efficacy of 
high-dose dexamethasone (Dex) vesus 100, 200, or 400 mg of thalidomide for up to 12 cycles in 
499 patients with relapsed/refractory MM, and demonstrated an improved time to progression 
(TTP) and response duration with all three thalidomide doses when compared to high-dose 
dexamethasone [45,46]. 
Thal/Dex was used in an Eastern Cooperative Oncology Group (ECOG) randomized trial of 202 
patients, where the best response with four cycles of treatment was significantly higher with 
Thal/Dex when compared to dexamethasone alone (63% vs. 41%, respectively; p = 0.002). 
Unfortunately, survival was not planned as an end-point for the study, and the analysis was not 
powered to compare differences in survival between both arms. Preliminary results from a separate 
randomized, double blind, placebo-controlled study comparing Thal/Dex with dexamethasone alone 
as primary treatment in 470 patients also confirmed these results [47]. These data led to the 
accelerated Food and Drug Administration (FDA) approval of Thal/Dex for newly diagnosed MM. 
Of additional interest is a case–control study that compared the efficacy and toxicity of Rev/Dex 
versus Thal/Dex in 411 patients with newly diagnosed MM, suggesting that the former is well 
tolerated and more effective as initial therapy, but this needs to be confirmed in randomized trials 
[48]. 
Rev/Dex has been tested in a phase 2 trial at the Mayo Clinic, and has shown impressive responses 
in patients with newly diagnosed MM [49]. The ECOG has also reported on a randomized trial with 
Rev/high-dose dexamethasone (RD: 40 mg days 1–4, 9–12, 17–20; 480 mg of dexamethasone per 
28 day cycle) versus Rev/low-dose dexamethasone (Rd: 160 mg of dexmethasone per 28 day cycle) 
showing a better short-term OS and lower toxicity with Rd [50]. 
Bortezomib-based regimens have demonstrated high response rates, which are between 70 and 80% 
with bortezomib plus dexamethasone; bortezomib, thalidomide, dexamethasone (VTD); or other 
bortezomib-based combinations (e.g. VMPT [bortezomib, melphalan, prednisone, thalidomide]; 
[51,52] (Table II)). 
 
 
Transplants and conditioning 
 
Current guidelines from Europe and the USA recommend that high-dose therapy and ASCT should 
be part of the initial therapy in younger patients with newly diagnosed MM with an adequate 
performance status [53]. As the biological age may differ from the chronological age, it is important 
to take associated comorbidities into account when determining whether a patient is a candidate for 
ASCT [18,19,26]; therefore, a strict age cut-off regarding ASCT is not always appropriate. While 
an upper age limit of 65–70 years is today's practice in Europe, in study protocols, patients up to the 
age of 75 years have been treated with age-adapted high-dose melphalan: melphalan 200 mg/m
2
 
(MEL200) is recommended for patients <65 years of age, whereas for fit elderly patients, doses of 
140 mg/m
2
 or 100 mg/m
2
 may be considered. For patients >75 years of age and/or with significant 
comorbidities, consideration should be given to reducing the dose of any given therapy. 
Although allo-SCT may be a potentially curative strategy [3,16,17], cure in MM still remains rare. 
Furthermore, the improvements in outcome seen over the past decade are almost certainly the 
culmination of a range of factors, including better patient selection for clinical trials and the 
administration of new treatment options, such as targeted conditioning therapies, the inclusion of 
novel agents into induction therapy, more intensive, yet non-myeloablative conditioning regimens, 
the use of tandem transplants, peripheral blood cells, graft engineering, post-transplant maintenance 
approaches, the adoption of specific and non-specific immunotherapies, and risk-adapted 
approaches for defined genetic abnormalities [54]. In this respect it is noteworthy that to date, 
del(17p13) remains a negative prognostic factor, whereas the adverse impact of t(4;14) might be 
overcome with allo-SCT [55]. 
Since it is safe and effective, ASCT as opposed to allo-SCT has become the standard of care in 
MM, with only 6% of transplant-eligible patients undergoing an allo-SCT while 94% receive an 
ASCT, thereby making MM the most common indication for ASCT worldwide [56]. Randomized 
trials have shown that ASCT is superior to conventional chemotherapy, resulting in an improved 
CR rate (22–44% vs. 5–8%) and a 12–30-month prolongation of event-free survival (EFS) and OS 
[12–15 ,54] (Table III). 
 
Table III. Novel agent combinations with autologous stem cell transplant (ASCT). 
 
Efforts to improve the efficacy and applicability of ASCT have prompted a series of randomized 
trials examing different conditioning strategies. Studies that compared a modified regimen using 
total body irradiation (TBI), busulfan, and cyclophosphamide (Bu/Cy) with MEL200 conditioning 
demonstrated equivalent OS rates but more toxicity with the TBI/Bu/Cy conditioning [57], thus 
supporting the continued use of MEL200. Similarly, earlier analyses had failed to show any 
advantages for Bu-conditioning [41] compared to MEL200. Furthermore, TBI added to MEL-
conditioning also failed to provide survival advantage compared to MEL200 [58] (EFS 21 months 
vs. 20.5 months, respectively); however, TBI was associated with more toxicity [59]. Finally, a 
randomized trial comparing early versus late ASCT demonstrated improved PFS for earlier 
transplantation (39 months vs. 13 months), while OS was not significantly different. Early ASCT 
was also associated with an improved quality of life and higher remission rates, thought to arise 
because of the better performance status of the patients with early ASCT who were also less heavily 
pretreated [60–70 ] and thus less likely to have multi-drug resistant disease. 
Future studies will need to more clearly define the benefit of ‘upfront’ ASCT versus deferring the 
procedure, as current data suggest that the median OS with early versus delayed ASCT may be 
similar, bearing in mind, of course, that with later-scheduled ASCT, patients may never actually get 
to transplant. Current transplant approaches, as summarized in Table III, utilizing novel induction 
regimens with single- or tandem-ASCT approaches have resulted in impressive response and OS 
rates. However, one the most important prognostic factors for achieving benefit from ASCT 
remains the ability to achieve CR. Failure to achieve CR or the loss of CR status is independently 
associated with inferior survival [27,71]. 
Currently, clinical trials in younger patients (<65 years of age) are exploring the concept of 
deferring early ASCT in favor of novel agent combinations such as dexamethasone and 
lenalidomide (Rd) or a triple-agent combination also including bortezomib (VRd). A trial of the 
GIMEMA study group is currently comparing four cycles of Rd induction followed by either six 
MPR (melphalan, prednisone, lenalidomide) cycles or tandem-ASCT with MEL200. Preliminary 
results suggest similar 1-year PFS and OS rates after three cycles of MPR versus MEL200 (96% vs. 
94% and 98% vs. 99%, respectively) [38]. While longer follow-up of these trials is awaited, the 
above recommendations for patients up to the age of 65 years with ASCT remain reasonable. In 
addition, the durability of the responses and the efficacy of salvage treatment after the use of novel 
agents are still unknown, whereas these data for ASCT are more mature. Finally, in patients without 
adverse prognostic factors, the life expectancy with ASCT is still more than 80% at 5 years, with a 
30% chance of long-term remission [53]. 
 
 
The issue of one versus two or more transplants 
 
A variety of strategies have been under evaluation to achieve higher CR rates in the first-line 
therapeutic setting; this includes the use of tandem-ASCT approaches, particularly for patients with 
insufficient response following an initial ASCT [72]. Studies comparing tandem- versus single-
ASCT have demonstrated improved CR rates by 1–15%, significantly prolonged EFS of 5–12 
months, and an OS benefit in one analysis [72–74 ]. However, the benefit of a second ASCT is 
probably restricted to patients failing to achieve a CR or very good partial response (VGPR) with 
the first ASCT. 
Despite treatment intensification, MM relapse usually occurs after ASCT and allo-SCT [1,3, 16,17], 
presumably because all patients harbor a proportion of MM cells with an anti-apoptotic phenotype 
conferring a high level of drug resistance. In this respect, the cell of origin of MM is still unclear, 
possibly arising in a plasmablast, a PC precursor, or even a more mature PC [2,75]. Moreover, 
transformation from primarily medullary (BM) to secondary extramedullary (EM) MM can evolve 
spontaneously or after ASCT [17], and it is theoretically possible that transplant strategies may 
select for more aggressive MM clones with unfavorable biology. Preliminary reports provide some 
evidence supporting this hypothesis [17,76]. 
  
Maintenance 
 
The growing number of therapeutic options for MM have significantly improved ORR, EFS, and 
OS for patients with MM; however, the tumor still remains incurable, with disease relapse being 
inevitable. Consequently, maintenance therapies appear to be a logical strategy for the prolongation 
of survival and are currently pursued worldwide. The ideal maintenance therapy should improve not 
only PFS and OS, but also quality of life, and therefore have few side effects and be easy to 
administer. Until now, only three anti-neoplastic agents—α-interferon (α-IFN), glucocorticoids, and 
thalidomide—have been adequately studied [77–94 ]. Maintenance with α-IFN is of only marginal 
benefit after either standard therapy or ASCT. A number of studies showed a trend toward 
improved response duration and relapse-free survival [77–81 ], but others failed to corroborate these 
findings [82–84 ], and OS was not prolonged by IFN treatment after standard therapy [77–84 ]. 
Furthermore, when administered after ASCT, the value of α-IFN-maintenance is similarly 
controversial, with only one study showing a PFS and OS benefit [61]. In this respect it is 
interesting to note that α-IFN seemed to be beneficial only in those patients with the lowest tumor 
burden and who had achieved at least a CR or VGPR after induction and ASCT [61]. These results 
and the emergence of alternative therapies that are less toxic, easier to administer, and potentially 
more effective have led to the abandonment of α-IFN as a maintenance therapy for MM [1,10]. 
Steroids are perhaps the simplest agents to give for maintenance therapy, but their efficiency has 
been tested in only a few studies, mostly after standard therapy. Contrary to α-IFN, OS and PFS 
could be prolonged significantly [94] with 50 mg prednisone on alternate days (so as to reduce the 
side effects related to chronic steroid exposure), and it was well tolerated [94]. Furthermore, when 
given with α-IFN, steroids were similarly well tolerated, reproducibly improved PFS [84,85], and in 
one study also improved OS after standard therapy [85]. Positive effects on ORR were also 
observed, if applied after ASCT [85]. Although the use of steroids is a promising approach and has 
found its way into clinical practice due to its easy application, tolerability, and low costs, the 
paucity of data that are available do not justify their general recommendation, but warrant further 
studies on benefits, side effects, and quality of life [86,87]. 
Promising maintenance strategies also include the use of novel agents, such as IMiDs, bortezomib, 
and others, either alone or in combination with other agents. Since these drugs directly target MM 
cells and their tumor microenvironment, they may be effective in interrupting cell-adhesion 
mediated drug resistance, and are potentially of particular use in the setting of a low tumor burden 
and minimal residual disease [86,87]. Thalidomide has been tested in several studies, mostly after 
ASCT, and when administered as a single agent, it significantly prolongs PFS, OS, and CR rates 
[88–91 ]. Feyler et al. showed that the doses used (five dose cohorts [50, 100, 200, 250, 300 mg] of 
100 patients) did not influence disease outcome, but greatly affected toxicity. Maintenance doses of 
>200 mg were largely unachievable, and peripheral neuropathy was the main toxicity, whereas 
lower doses enabled more patients to stay on the drug for more prolonged periods of time with 
fewer side effects [89]. As anticipated with the lower doses as currently used (usually 50–200 
mg/day), thalidomide was more effective when used for maintenance than for relapse [40,89]. 
Importantly, in this respect, two subsets of patients do not appear to benefit from thalidomide 
maintenance, those with 13q14 deletion (del13) and patients achieving a VGPR [40,91], which 
implies that for patients with del13, alternative strategies need to be developed and that thalidomide 
should be stopped with the achievement of a VGPR in order to reduce toxicity and the development 
of drug resistance. However, it should be noted that these studies were not designed or powered to 
answer questions in relation to the outcome of patient subsets. The incidence of resistance during 
thalidomide maintenance and its influence on repeated thalidomide usage in subsequent salvage 
therapy regimens have also been investigated [91,92]. Whereas some earlier trials suggested 
unfavorable effects on subsequent salvage therapies after initial thalidomide exposure [85,91], 
others have found similar responses to the drug on second exposure [15]. Further studies have also 
shown the efficiency of thalidomide on OS and PFS when combined with steroids and interferon 
[1,93]. In this regard, thalidomide was well tolerated in a dose of up to 200 mg, if administered 
alone or with steroids [40,88–91 ,93], whereas, not surprisingly, tolerability decreased substantially 
when used in combination with interferon. Neuropathy is the most common side effect, followed by 
fatigue and constipation [15,40,88–93 ], while thrombotic events were not statistically increased 
with thalidomide maintenance [15,40,88–92 ], suggesting that when given later in the course of the 
disease following de-bulking of tumor, the thromboembolic risk is much less than at diagnosis. This 
underlines the importance of the association between tumor mass and thrombosis when thalidomide 
is administered, and has led to risk-adapted antithrombotic recommendations [95]. In summary, 
thalidomide is an attractive and effective option for MM disease maintenance approaches and is still 
being studied in clinical trials. 
Similarly, bortezomib and lenalidomide are being evaluated in ongoing clinical trials [96–101 ]. 
Preliminary results suggest that bortezomib maintenance may favorably impact on the time to MM 
recurrence after ASCT, and is being investigated in MM trials in both younger (<60 years) and 
older patients (e.g. DSMM trials). The use of a therapy regimen that combines bortezomib, 
thalidomide, and dexamethasone (VTD) as maintenance treatment in 19 patients who had achieved 
a VGPR or CR demonstrated a reduction of the clonal cell burden as assessed by real time-
polymerase chain reaction (RT-PCR); however, in most patients, VTD was unable to completely 
reduce the tumor load below the sensitivity threshold with PCR-based approaches [102]. Moreover, 
after initial anti-MM treatment, VTD could perhaps be considered more as a consolidation approach 
rather than ‘maintenance,’ and may not be well tolerated for prolonged periods of administration. 
 
 
Novel agents 
 
Thalidomide/dexamethasone (TD) has been compared to VAD as induction before ASCT, 
demonstrating superior pre-ASCT responses but with no difference in ORR post-ASCT (Table III). 
In contrast, the Intergroup Francophone du Myelome (IFM) have reported preliminary results from 
a randomized trial comparing bortezomib/dexamethasone (VD) to VAD pre-ASCT, and with more 
than 400 patients enrolled they demonstrated significantly superior response rates with VD both 
before and after ASCT [52]. As bortezomib use does not compromise stem cell mobilization, it is 
currently under evaluation as a component in a variety of other induction protocols (e.g. 
cyclophosphamide, dexamethasone, and bortezomib in the DSMM XI trial) [103,104], with a 
randomized trial of bortezomib, thalidomide, and dexamethasone (VTD) showing superior 
responses when compared to TD (Table III). Lenalidomide with lower dexamethasone doses (Rd: 
160 mg of dexamethasone per 28 day cycle) has been compared to lenalidomide with standard high-
dose dexamethasone (RD: 480 mg of dexamethasone per 28 day cycle). Both regimens induced 
high response rates, but the former schedule resulted in fewer infectious complications than the 
former and was thus overall better tolerated (Table III) [41,50,105]. 
While bortezomib, thalidomide, and lenalidomide have already been integrated into anti-MM 
schedules, there are many other promising therapeutic agents being used in early clinical trials. 
These include carfilzomib [106–108 ], pomalidomide [109,110], multikinase inhibitors (MKIs), 
antiangiogenic approaches, antibodies, arsenic trioxide, farnesyl transferase (FTI)-, histone 
deacetylase (HDAC)-, heat shock protein-90 (HSP-90)-, and PI-3K/PKD/mTOR-inhibitors, and 
various other agents which can stabilize relapsed and/or refractory MM. Within this context, clearly 
the challenge will be to identify subgroups of patients who will benefit most from the different 
agents and to incorporate targeted therapies into the management on the basis of an increased 
understanding of the biology of MM [1,2,75, 111,112]. 
 
 
Allografting in the era of new drugs 
 
Myeloablative allo-SCT has been largely abandoned in MM management because of unacceptably 
high transplant-related mortality (TRM). In the late 1990s, the introduction of non-myeloablative 
and reduced intensity conditioning (RIC) regimens, which rely on a putative graft-versus-MM 
effect, have dramatically reduced TRM to <15%, while achieving CR rates of up to 53–73% and 
increasing the upper age limit for transplant to 65–70 years [113,114]. Although 30–35% of patients 
obtain prolonged disease control and may even be cured, relapse and disabling chronic graft-versus-
host disease (GVHD), in a subset of patients, remain matters of concern. Fortunately, relapsed 
disease post-allo-SCT is amenable to salvage therapies, including the use of novel therapies [115], 
and importantly, preliminary data suggest that the maintenance of a graft-versus-MM effect and the 
administration of novel agents are not mutually exclusive. Agents such as bortezomib may also 
contribute to reducing the incidence and severity of GVHD [116]; however, despite these advances, 
the role and timing of allo-SCT in the era of new drugs still remain to be determined, particularly as 
recently published outcomes with allo-SCT are from studies initiated before the availability of 
novel agents. 
 
 
Initial therapy in elderly patients 
 
In the elderly, the three most commonly used regimens are combinations of melphalan, prednisone, 
and thalidomide (MPT; grade A recommendation, level Ia evidence); of melphalan, prednisone, and 
bortezomib (MPV; grade A recommendation, level Ia evidence); and of melphalan, prednisone, and 
lenalidomide (MPR; grade B recommendation, level IIa evidence). 
Several studies have compared MP versus MPT in elderly patients with newly diagnosed MM, all 
consistently reporting that MPT resulted in higher ORR and longer PFS [15,117–119 ]. A recent 
meta-analysis has confirmed the superiority of MPT in terms of response and survival [120]. These 
results support the use of MPT as one of the standards of care in elderly patients with MM, bearing 
in mind that neurological adverse events, infections, cardiac toxicity, and thromboembolism are 
increased with MPT when compared to MP. Antithrombotic prophylaxis is recommended according 
to risk factors as previously described [95], and the doses of thalidomide need to be adjusted based 
on tolerance in the elderly so as to minimize toxicity. In patients >75 years of age, the 
recommended dose is 100 mg/day [118]. 
MPV resulted in significant improvements in ORR, time to progression, and OS compared to MP; 
however, the incidence of peripheral neuropathy, gastrointestinal complications, and herpes zoster 
infection was higher with MPV. When comparing MPV with bortezomib, thalidomide, and 
prednisone (VTP), there were no differences in ORR, but MPV had less non-hematologic adverse 
events than VTP. The thalidomide plus MPV (VMPT) regimen induces even higher VGPR and CR 
rates than MPV, and an ongoing randomized study of VMPT versus VMP suggests an improved 2-
year PFS of 70% vs. 58%, but with no difference in 2-year OS rates (89.6% and 89%, respectively), 
with longer follow-up clearly needed [121]. Finally, preliminary data suggest that with weekly 
instead of twice-weekly bortezomib infusions, with or without thalidomide combinations, the 
incidence of grade 3/4 peripheral neuropathy can be reduced without substantially compromising 
ORR [122,123]. 
MPR has been tested in a single-arm study of 54 newly diagnosed patients >65 years and induced 
an ORR of 81%, with a VGPR rate of 47.6%, median time to progression and PFS of 28.5 months, 
and a 2-year OS of 90.5% [124]. This led to the initiation of a three-arm phase III trial comparing 
MPR-R (MPR followed by lenalidomide maintenance) versus MPR versus MP, and an ECOG trial 
comparing MPR versus MPT. In the former trial, with a median follow-up of 9.4 months, early 
results show a PFS which has not yet been reached with MPR-R, versus 13 months with MP, and a 
1-year OS-rate of 92% [125]. Interestingly, however, the PFS with MPR is the same as with MP 
(both 13 months), in contrast to the previously reported non-randomized trial of MPR showing a 
PFS of 28.5 months [124,125]. 
 
 
Treatment of relapsed/refractory disease 
 
IMiD and bortezomib combination schedules as described in Tables II and IV have become part of 
standard practice, and are continuing to be evaluated in ongoing clinical trials. Combination 
schedules as depicted in Table IV have demonstrated high levels of activity in relapsed/refractory 
(RR) MM and now need to be tested in larger patient cohorts, with longer observation periods and 
optimally compared against each other. An increased range of therapeutic options for RR MM have 
become available in the past decade, with patients relapsing after the year 2000 demonstrating a 12-
month improvement in survival from the time of relapse compared to those who relapsed before this 
date (23.9 months vs. 11.8 months) [126]. However, in the context of RR MM many questions 
remain unanswered, the most prominent being whether all active agents should be used at the same 
time or sequentially, and whether single-, double-, triplet- or four-drug combinations are optimal. 
Thus, the therapeutic management of RR MM patients depends on various factors, including: prior 
drug exposure and efficacy, the clinical characteristics of the RR MM, and patient characteristics. A 
detailed understanding of drug combinations used previously and the degree and duration of 
response is critical for the decision about what relapse treatment should be used, since—if aggresive 
relapse occurs—multidrug combinations may be preferable. Relevant patient characteristics include 
comorbidities, performance status, bone marrow reserve, organ (particularly renal) function, age, 
and previously experienced or persisting therapy-related toxicities. In young patients relapsing early 
after ASCT (<1 year), the goal should be to overcome drug resistance, and therefore one would 
favor a combination of available potentially effective drugs such as bortezomib, lenalidomide, 
dexamethasone, and cyclophosphamide, or perhaps bortezomib, dexamethasone, thalidomide, 
cisplatin, adriamycin, cyclophosphamide, and etoposide. If a good response is achieved, the patient 
could proceed to allo-SCT or maintenance therapy. If the relapse occurs >3 years after ASCT, an 
option would be to reintroduce the initial treatment or another novel agent combination followed by 
a second ASCT. In the intermediate situation, with relapse occurring 1–3 years after ASCT, one 
might favor attempting to rescue the patient with novel agents, but used in a sequential rather than 
simultaneous manner. In elderly patients, considerations concerning quality of life, travel distance 
to the hospital, patient's wishes, and the cost of therapy need to be carefully balanced also. At first 
relapse a logical choice would be to use a new treatment scheme; at second relapse—usually after 
having received treatment with bortezomib and an IMiD—a clinical trial with experimental agent(s) 
should be encouraged [1,33,127]. 
 
 
 
 
 
 
 
 
 
 
 
Table IV. Clinical phase II and III studies in relapsed and/or refractory patients. 
 
 
 
Supportive care for multiple myeloma-induced and/or -associated 
complications 
 
Bone disease  
 
Despite substantial innovations in the antineoplastic treatment of MM, specific supportive therapies 
play a key role in patient management and contribute significantly to what should be considered as 
optimal patient care. Approximately 80% of patients with MM display lytic bone lesions and/or 
diffuse osteopenia. Bisphosphonates, which substantially inhibit bone destruction and reduce 
skeletal related events, are recommended for patients with MM with bone disease [128,129], and do 
not require the use of biochemical markers of bone metabolism to monitor their use [130,131]. In 
addition, bisphosphonates have a beneficial impact on pain control, particularly with pain due to 
osteolytic disease [132]. Other advances in the management of MM bone disease include the use of 
vertebroplasty and kyphoplasty to treat vertebral fractures. Currently, the international standard for 
bisphosphonate therapy remains intravenous zoledronic acid 4 mg or pamidronate 90 mg every 3–4 
weeks in stage II and III disease. Physicians employing bisphosphonates may wish to consult the 
updated American Society of Clinical Oncology (ASCO) [130] and other available guidelines on 
the use of bisphosphonates [129]. Serum creatinine should be monitored before each 
bisphosphonate application, and the dosage must be reduced in patients with preexisting renal 
insufficiency (estimated glomerular filtration rate [eGFR] 30–60 mL/min/m2). Furthermore, it is 
mandatory to monitor serum calcium, electrolytes, phosphate, magnesium, and 
hematocrit/hemoglobin regularly [130] in the context of bisphosphonate use. 
Osteonecrosis of the jaw (ONJ) is a rare but potentially serious side effect associated with the usage 
of bisphosphonates. However, other important risk factors for its occurrence are invasive dental 
interventions and oral infections prior to bisphosphonate use. Because of this, patients should be 
advised to undergo a dental examination before bisphosphonate use and to employ appropriate oral 
hygiene while being treated [133–136 ]. Additional risk factors for the development of ONJ are the 
type and duration of exposure to bisphosphonates. Multimodal therapeutic approaches to this 
problem have used systemic antibiotic therapy, hyperbaric oxygen therapy, laser therapy, topical 
use of chemotherapeutic mouth rinses, and discontinuation of bisphosphonates [133], but no 
accepted standard approach to the treatment of established ONJ has yet been identified. 
Importantly, however, preventive measures have been shown to reduce the incidence of ONJ by 
75% [129]. Zervas et al. have suggested that patients receiving zoledronic acid may have a higher 
risk of ONJ than patients treated with pamidronate [137], but conversely, zoledronic acid is 
probably more effective in counteracting the development of skeletal complications [138]. Current 
guidelines suggest that in the presence of stable MM, one should consider stopping bisphosphonates 
after 2 years of treatment, with a view to re-starting therapy in the context of recurrent MM. 
Renal impairment  
Renal impairment (RI) early in the natural history of MM is nowadays considered a less frequent 
problem due to earlier diagnosis and the more effective induction therapies that are available; 
nevertheless, with substantially longer OS, a significant proportion of patients will develop late 
disease complications, including RI. Milder degrees of RI are observed in 25–50% [18] of patients, 
and during disease progression RI develops in at least 20% of patients. Many factors may contribute 
to RI including dehydration, infections, hypercalcemia, and nephrotoxic drugs. It has also been 
suggested that RI can be a predictor of poor prognosis since it may reflect a higher MM burden. 
Furthermore, therapeutic dose reductions may be needed in these cases, and treatment related 
mortality (TRM) has been shown to be increased in RI-affected patients [18]. Current analyses are 
evaluating the development of new treatment approaches for patients with RI where prompt disease 
control is crucial, with new agents, particularly bortezomib, holding great promise for the rapid 
reversal of RI [139–141 ]. 
Hematologic toxicity  
Approximately 70% of patients with MM have anemia resulting either from the disease itself or 
from their anti-MM therapy, and this can be treated with the recombinant hematopoietic growth 
factor erythropoietin (EPO). Evidence-based guidelines suggest using EPO when the hemoglobin 
levels fall below 10 g/dL, and for patients with persistent symptomatic anemia. Evidence from 
clinical trials supports the use of subcutaneous EPO titrated once the hemoglobin concentration 
reaches 12 g/dL [142]. Prutchi-Sagiv et al. claimed that EPO used in the early stages of MM might 
boost the immune system and therefore induce an anti-MM effect [143], but other trials have 
suggested that EPO treatment might have deleterious effects on tumor response and survival, thus 
tempering the enthusiasm for its use [11,33,144]. Well-known EPO-induced side effects, 
particularly the increased risk of thrombosis, need to be taken into consideration, especially when 
used in conjunction with IMiDs [11,33,144]. 
Infection  
Infection is the single most dangerous complication for patients with MM, since disease and therapy 
impair both cell-mediated and humoral immunity. Patients with MM show an increased 
susceptibility to viruses, bacteria, mycobacteria, fungi, and other pathogens, and therefore require 
thorough infection monitoring and appropriate use of prophylactic antibiotics. In addition, all 
patients after allo-SCT should receive vaccinations for diphtheria, tetanus, hemophilus, influenza 
viruses including H1N1, poliovirus, measles, mumps, rubella, and Streptococcus pneumoniae, 
whilst for patients with ASCT, vaccinations against influenza and Streptococcus pneumoniae are 
recommended [33,145–148 ]. 
 
 
Conclusions and perspectives toward the road to cure MM 
 
Modern treatment approaches provide safe and highly effective therapy, and a substantial 
proportion of younger patients with MM survive for more than 10 years [1,10,126,149]. Although 
residual disease may be detectable with molecular methods, current therapy aims at achieving a 
normal life for patients with MM, with minimization of disease-related symptoms or complications. 
The most promising therapeutic approach in younger (<65 years) patients is the combination of 
transplant procedures (ASCT ± RIC allo-SCT) and targeted therapies. In elderly patients (>65 
years), MPT or MPV can be considered the standard of care, while dose-reduced tandem-ASCT 
(MEL140) with novel induction therapies (e.g. lenalidomide/low-dose dexamethasone, Rd) are 
currently being tested against standard regimens (e.g. DSMM XIII trial), and results are awaited 
with anticipation. 
An increased understanding of the pathobiology of MM has translated into a broadened spectrum of 
available targeted therapies (Figure 2), which may result in further improvement in patient outcome 
and quality of life. The discovery of microRNA (miRNA) genes, encoding for a class of small non-
coding RNAs acting as negative regulators of gene expression, has added a further level of 
complexity to our concept of MM cancer biology. It has been reported that the combination of non-
random chromosomal abnormalities and other types of genetic alterations or epigenetic events 
contribute to downregulation or overexpression of miRNAs, which may consequently affect the cell 
cycle, cell survival, and cellular differentiation programs [150]. MM represents an ideal model for 
miRNA investigation, since it is associated with recurrent deletions or gains/amplifications that may 
affect the normal miRNA role. Significant data concerning miRNA in MM have been reported only 
recently by various groups, showing signatures associated with specific molecular types and 
suggesting that distinct miRNAs may play an important role in neoplastic transformation and 
disease progression [151–154 ]. Experimental data have also recently suggested that miRNA-15a 
and miRNA-16, which are located in the 13q14 region, frequently deleted in MM, may play a role 
in MM cell proliferation, representing promising targets for novel therapies [155]. 
 
Figure 2. Myeloma network of interacting factors between myeloma cells and cells from the 
microenvironment (figure modified with kind permission according to illustrations of 
Hideshima et al., 2002 [186], Hideshima et al., 2007 [187], and Harousseau, 2009 [185]). The 
diagram shows the interplay between myeloma, microenvironment, chemo-, cytokines, and 
signaling molecules involved in the pathophysiology of MM and various treatment options 
that mediate their action through direct cytotoxicity, apoptosis induction, anti-angiogenesis, 
and/or immunostimulation. MM, multiple myloma; CAMDR, cell adhesion-mediated drug-
resistance; BMSC, bone marrow stromal cell; BMECs, bone marrow endothelial cells; HGF, 
hepatocyte growth factor; OPG, osteoprotegerin; IL-6, interleukin 6; NFκB, nuclear factor 
κB; RANK, receptor activator of NFκB; RANKL, receptor activator of NFκB ligand; VEGF, 
vascular endothelial growth factor; bFGF, basic fibroblast growth factor; IGF-1, insulin like 
growth factor-1; SDF-1α, stromal-cell-derived-factor-α; TGFβ, transforming growth factor β; 
ICAM-1, intercellular adhesion molecule 1 ; VCAM-1, vascular adhesion molecule 1 ; 
PI3K, phosphatidylinositol 3-kinase; MIP-1α, macrophage inflammatory protein 1α; LFA-1, 
lymphocyte function antigen 1 ; MUC-1, mucin protein 1 ; VLA-4, very late antigen 4 
; DKK1, Dickkopf 1; MIP1α, macrophage inflammatory protein 1α; TNFα, tumor necrosis 
factor α. 
 
 
 
 
Novel prognostic tools are also being extensively explored, and cyclins functioning as cell cycle 
regulators have proved to be of interest, since overexpression of the cyclin genes CCND1, 2, and 3 
are recurring abnormalities in human cancer. Recent studies have demonstrated a positive 
association between CCND1 overexpression and survival in breast cancer and MM. Paradoxically, 
high cyclin D expression should enhance proliferation and sensitivity to chemotherapy, but MM is 
characterized by a very low proliferative index [2,156] and drug resistance. However, another 
explanation for the association between high cyclin D levels and better prognosis could be the 
binding of the anti-apoptotic transcription factor signal transducer and activator of transcription 3 
(STAT3) to CCND1, as described in breast cancer [157]. CCND1 represses STAT3 transcriptional 
activity, thereby inducing apoptosis and causing less aggressive tumor growth. As the CCND1 
protein has a short half-life due to post-translational regulation by ubiquitination and proteasomal 
degradation, this might provide a therapeutic rationale for blocking CCND1 degradation using a 
26S proteasome inhibitor, and consequently amplifying anti-tumorigenic activity [158,159]. 
Together with in vitro and vivo analyses, these new basic discoveries relating to gene regulation in 
tumorigenesis are likely to lead to the development of new treatment options as well as a better 
understanding of MM pathobiology, and will hopefully further improve the development of future 
MM treatment [112,160]. 
Two studies in particular have shown that advances in MM care and treatment do translate into 
improved survival. Brenner et al. demonstrated that between 1990–1992 and 2002–2004, the 5-year 
OS for MM has increased from 28.8 to 34.7%. The most significant change occurred in younger 
patients (<50 years), with 5- and 10-year OS rates of 56.7% and 41.3%, respectively [161]. In a 
second study, Kumar et al. demonstrated that patients who relapsed after SCT and were treated with 
novel agents had a significantly improved median OS of 30.9 months, compared to only 14.8 
months for patients not receiving novel agents. Importantly, they also showed that the OS of 
patients with newly diagnosed MM has improved by 50% over the past decade, albeit in a tertiary 
referral center [126]. Despite these impressive advances in MM therapy, there are still important 
challenges to overcome in the future [1,3,10,11,162]. In addition to targeted therapies, 
chemotherapeutic regimens with increased antineoplastic efficiency are still needed, since the major 
cause of relapse after ASCT is the resistance of MM cells to currently available cytotoxic agents. 
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